Clinical trialPhase 1Unknown
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 20 January 2022
- Listed end
- 15 December 2025
- Enrollment
- 70 participants
- Sites
- 8
- Primary outcomes
- Incidence and severity of adverse events and serious adverse events; Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 22 October 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer